Results 71 to 80 of about 236,152 (278)

Nail Psoriasis in a Child Observed Under Ultraviolet Dermoscopy Treated by a Topical Biological Agent Cream: A Case Report

International Journal of Dermatology and Venerology, 2021
. Introduction:. Nail psoriasis is a type of psoriasis involving nail lesions characterized by pitting, onycholysis, longitudinal ridges, and subungual hyperkeratosis.
Run-Yan Gao, Sushmita Pradhan, Yu-Ping Ran   +2 more
doaj   +1 more source

Psoriasis confined to the nails

Dermatology Online Journal, 2003
A case is presented of a 49-year-old man with psoriasis limited to the nails for 12 years. The patient had no evidence of psoriasis elsewhere. He had been treated with a year-long course of griseofulvin and 2 months of weekly fluconazole without effect before the diagnosis of psoriasis was made by biopsy of the lateral nail fold.
openaire   +4 more sources

Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis

Acta Dermato-Venereologica, 2020
The comparative efficacy of registered anti-psoriatic biologics and small molecules in treating nail symptoms has not been systematically evaluated. The aim of this study was to perform a network meta-analysis to determine the efficacy of biologics and ...
Júlia Szebényi, Noémi Gede, Péter Hegyi, Zsolt Szakács, Margit Solymár, Bálint Erőss, András Garami, Kornélia Farkas, Dezső Csupor, Rolland Gyulai   +9 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management

Dermatologic Therapy, 2021
Nail psoriasis has a prevalence that ranges from 10 to 82% and can significantly impact the quality of life of patients. Nail psoriasis is one of the most challenging areas to treat, and multiple therapies have been explored.
E. Hadeler, M. Mosca, Julie J. Hong, Nicholas D. Brownstone, T. Bhutani, W. Liao   +5 more
semanticscholar   +1 more source

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0–3) and Short Form‐36 PF subscale (SF‐36, 0–100); radiographic joint damage was measured ...
Pankti Mehta, Shangyi Gao, Virginia Carrizo Abarza, Fadi Kharouf, Daniel Pereira, Richard J. Cook, Dafna D. Gladman, Vinod Chandran, Denis Poddubnyy   +8 more
wiley   +1 more source

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

Journal of dermatological treatment (Print), 2021
Background Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.
K. Reich, C. Conrad, L. Kristensen, Saxon D. Smith, L. Puig, P. Rich, C. Sapin, Thorsten Holzkaemper, U. Koppelhus, C. Schuster   +9 more
semanticscholar   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Topical Tretinoin in the Treatment of Nail Psoriasis

Indian Dermatology Online Journal, 2022
© 2022 Indian Dermatology Online Journal | Published by Wolters Kluwer Medknow Sir, A 12‐year‐old girl presented with asymmetric fingernail involvement with distal nail disease in the form of subungual hyperkeratosis, distal onycholysis with proximal ...
C. Grover, D. Daulatabad
semanticscholar   +1 more source

Nail Psoriasis

Muneer H, Sathe NC, Masood S.
europepmc   +3 more sources